Alberto Sánchez-Fueyo, MD PhD, is Professor of Hepatology, Academic Head of the Institute of Liver Studies at King’s College London, and Honorary Transplant Hepatology Consultant at King’s College Hospital.

His research has focused on understanding the mechanisms of immunological tolerance in transplantation and developing novel immunomodulatory therapies, for which he has received funding from MRC, NIHR, NIH and EU, among others. Additional research interests include the generation of genetically engineered regulatory T cells for immunotherapeutic purposes, which is now being pursued in collaboration with Quell Therapeutics, a King’s spin-off biotech which he contributed to found in 2019.